Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD)

Documents similaires

• Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease
  par: Tsung‐Hua Shen, et autres
  Publié: (2024)
• SGLT‐2 Inhibitors Use in Hospitalized Patients in France: A Cross‐Sectional Study
  par: Maxime Demourgues, et autres
  Publié: (2026)
• Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction‐associated steatotic liver disease: A retrospective nationwide claims database study in Japan
  par: Mitsuhiro Shikamura, et autres
  Publié: (2024)
• JAK/STAT inhibitors mitigate sepsis‐associated cerebral and cognitive injury
  par: Mohini Singh Bhadauriya, et autres
  Publié: (2025)
• Weight and mortality in people living with HIV and heart failure: Obesity paradox in the era of glucagon‐like peptide 1 (GLP‐1) receptor agonists and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors
  par: Natalia Nazarenko, et autres
  Publié: (2025)